Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
OSLO, NORWAY, January 27, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA’s Chief Technology Officer Kari Furu was a finalist in the Lyfebulb 2022 Innovation Challenge in collaboration with Bristol Myers Squibb (“BMS”) to address unmet needs in Inflammatory Bowel Disease (“IBD”). Kari presented GA’s IBD Biomarker Project to an expert jury spanning business, venture capital, and healthcare industries in a summit at BMS' premises in Princeton, New Jersey on 25[th] January.Kari Furu was selected in December 2022 as one of ten finalists in the